The findings suggest that beta-blockers and other drugs that help restore balance to the autonomic nervous system may have ...
Research indicates β-blockers may reduce the risk of motor diagnosis and slow symptom progression in Huntington's disease, ...
Swiss drugmaker Novartis will pay up to $2.9 billion for PTC Therapeutics' promising experimental drug for a neurological ...
Novartis is paying $1 billion upfront for global rights to PTC Therapeutics’ midphase Huntington's disease program, helping ...
Monday’s agreement comes days after PTC discontinued the development of another asset, utreloxastat, due to disappointing ...
Tapering. Spaghetti plots show that CSF NFL (right) rises more quickly in people with ADAD mutations (red) than in noncarriers (gray) and that this accelerates as disease progresses. In plasma (left), ...
The Wicked Witch of the West and I have something in common: We both use our fatal flaws to our advantage—for her, her green ...
Madison Elsaadi, an analyst from B.Riley Financial, reiterated the Buy rating on Wave Life Sciences (WVE – Research Report). The associated ...
Novartis will make an upfront payment of $1.0 billion to PTCT and the latter will also be eligible for up to $1.9 billion in ...
A common heart drug has shown promise to delay the onset of Huntington's disease -- a progressive and inherited brain ...
Beta-blocker drugs -- commonly used to treat heart and blood pressure issues -- may slow the progression of Huntington's disease (HD), according to a new study.
Opens in a new tab or window Beta-blocker use was tied with slower symptom progression in people with early motor-manifest Huntington's disease. In a people with genetically confirmed premanifest ...